Ocrelizumab biosimilar (Prestige BioPharma)
N/A
Report date: 2024/10/10 10:04:54
Base Information
Drug NameOcrelizumab biosimilar (Prestige BioPharma)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPrestige BioPharma Ltd
China Registration ClassN/A
Develop Information
Active CompaniesPrestige BioPharma Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A